2-halo-2'-deoxyadenosine treatment for histiocytosis

Details 2-halo-2'-deoxyadenosine treatment for histiocytosis 2-halo-2'-deoxyadenosine treatment for histiocytosis

1994-09-06

1996-04-23

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 2763, A61K 3170

Patent

active

055103367

ABSTRACT:
An improved method for treating Class I histiocytosis, Langerhans cell histiocytosis, is disclosed. In accordance with that method, a therapeutically effective amount of a 2-halo-2'-deoxyadenosine is administered to a host mammal such as a human patient having histiocytosis in an amount of about 0.5 to 0.9 mg/kg of body weight over a course of about 5 to 9 days for up to two courses.

REFERENCES:
patent: 5106837 (1992-04-01), Carson et al.
patent: 5310732 (1994-05-01), Carson et al.
patent: 5401724 (1995-03-01), Beutler
patent: 5424296 (1995-06-01), Saven et al.
Favara (II), "Langerhans' Cell Histiocytosis Pathobiology and Pathogenesis," Seminars in Oncology, 18(1), 3-7 (1991).
Komp et al, "Introduction: The Histiocytic Syndromes," Seminars in Oncology, 18(1), 1-2 (1991).
Willman et al, "Langerhans'-Cell Histiocytosis (Histiocystosis X)-A Clonal Proliferative Disease," The New England J. of Medicine, 331(3), 154-160 (1994).
Komp, "Langerhans' Cell Histiocytosis," The New England J. of Medicine, 316(12), 747-748 (1987).
Gotoh et al., "Induction of Unresponsiveness to Islet Allograft by Anti-LFA-1 Monoclonal Antibody Treatment," Transplantation Proceedings, 25(1, Book II), 973-974 (1993).
Chapal et al., "Effects of Adenosine, Adenosine Triphosphate and Structural Analogs on Glucagon Secretion from the Perfused Pancreas of Rat In Vitro," British J. Pharmacology, 83, 927-933 (1984).
Berkow et al. (eds.), Merck Manual of Diagnosis and Therapy, Sixteenth Ed., Merck Research Labs., Rahway, NJ, 1992, see pp. 720, 1354-1355 & 2206-2211.
Saven et al. (II), "2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis X," N. Engl. J. Med., 329(10), 734-735 (1993).
Saven et al. (III), "2-Chlorodeoxyadenosine-induced Complete Remission in Langerhans-Cell Histiocytosis," Annals Internal Medicine, 121(6), 430-432 (1994).
Saven, et al., The New Engl. Jrnl. of Med., pp. 734-735, Sep. 2, 1993.
Histiocytosis Syndromes Classification, Diagnostic Features and Current Concepts Blaise E. Favara, Leukemia and Lymphoma, 2:141-150, Sep. 14, 1989.
Histiocytosis Saven, et al., Annals of Internal Medicine, No. 6, 121:3 pgs., Sep. 15, 1994.

Affiliated with

Also associated with

Rating

2-halo-2'-deoxyadenosine treatment for histiocytosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-halo-2'-deoxyadenosine treatment for histiocytosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-halo-2'-deoxyadenosine treatment for histiocytosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2308535